ACM Biolabs appoints David Lawrence to its Board as Non-Executive Director

– SINGAPORE, Singapore –  ACM Biolabs (EPA: ALSEN) a pioneering Singaporean-Swiss biotechnology company, which specializes in the development of targeted therapeutics for the prevention of multiple life-threatening diseases based on its proprietary ACM tunable polymer-based delivery ATP™ technology, today announced the appointment of David Lawrence to its Board as a Non-Executive Director.

About David Lawrence

Mr. Lawrence is the CFO of Sensorion, a gene therapy company listed on Euronext Growth in Paris, and is a Director at EnteroBiotix Ltd. He was previously CFO of Valneva, a specialty vaccine company, where he served as a member of the Management Board; his responsibilities included Investor Relations and Communications in addition to overseeing the financial management of the company. During his tenure at Valneva, he was instrumental in several financings including a NASDAQ Initial Public Offering and by the point of his retirement from Valneva the market capitalization of the company had grown to over €2bn. He also previously served as CFO of Acambis and VP of Finance, Business Development, and Strategy at Chiron Vaccines. In 2011 he supported the establishment and development of Synpromics Ltd, a synthetic promoter company that was acquired by AskBio in 2019, which was in turn acquired by Bayer in 2020.

Mr. Lawrence has over 30 years experience of in leadership roles in life sciences, ranging from large biopharma companies such as GSK to start-ups and earlier-stage companies, including Synpromics Ltd. He brings with him extensive industry experience including strategy, business development, and M&A, and currently sits on the Boards of Enterobiotix Limited. He has also advised several life sciences Venture Capital firms between 2006 and 2017.

About ACM Biolabs

ACM Biolabs is a pioneering Singaporean-Swiss biotechnology company with a versatile clinical platform for disease prevention and therapeutics based on its proprietary ACM (Artificial Cell Membranes) polymer-based delivery technology. ACM Biolabs’ Tunable Platform, offers flexibility to deliver multiple payloads and can successfully target specific organs. Current R&D efforts focus on developing vaccines for infectious diseases and personalized cancer therapeutics.

ACM Biolabs’ lead program, ACM-001 an adjuvanted SARS-CoV-2 spike protein intranasal vaccine, has demonstrated pre-clinical efficacy and safety, with the potential to disrupt viral transmission and mutation. Its phase 1 clinical trial has progressed with no adverse safety signals in cohorts 1-6 and full immunogenicity data is expected in the coming weeks. The ACM-001 program also validates the clinical efficacy of the ACM polymer-based platform, enabling a wider range of clinical applications.

ACM Biolabs leads all clinical and regulatory activities of its pipeline programs. It also coordinates business development discussions with potential partners, to leverage ATP for the formulation and targeted delivery of novel pipeline candidates.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.